Tests radiofrequency ablation with liver surgery for colon cancer spread to the liver
Tests heat ablation during liver surgery in adults with colon cancer spread to the liver.
Plain-language title generated from the registry record
Registry title: Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
Key facts
- Where
- Aarhus, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver metastases from colorectal cancer who are planned for surgery to remove them. It tests radiofrequency ablation (RFA) as an added treatment.
- Age
- 18 to 99 years
- Sex
- All sexes can join.
- Disease stage
- Colorectal cancer that has spread to the liver, with surgery planned. At least one tumor is 3 cm (1.2 in) or larger.
- Earlier treatment
- People who have already had RFA treatment cannot join.
Main reasons for not taking part
- Liver cirrhosis
- Cancer outside the liver that cannot be treated with the aim of removing all of it
- Another cancer in the 5 years before the diagnosis
- Earlier RFA treatment
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT04798898, who can take part
Where in Denmark
- Aarhus University Hospital, Department of SurgeryAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT04798898
- Record updated
- 5 December 2024
- Original description
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.Read full original descriptionShow less
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
Inclusion: Patients with colorectal liver metastases planned for resection; At least one tumor size >=3cm; Performance status 0-1.
Exclusion: Other malignant diseases within 5 years prior to diagnosis; Prior RFA treatment; Liver cirrhosis; Extrahepatic metastases that can not be addressed curatively.